Metabolomics Global Market to Reach $17.1 Billion

North America Accounts for the Largest Regional Market Share

February 26, 2019

WELLESLEY, Mass., Feb. 26, 2019–Rapid growth in the metabolomics global market is expected through 2023, according to the BCC Research reportMetabolomics: Technologies and Global Markets.” Changes in technical fields such as bioinformatic solutions, mass spectrometry, chromatography and multi-omics are driving new products and applications in metabolomics, paving the way for unique market opportunities.

The major drivers of market growth are increasing investment in metabolomic research through public and private funding, increasing applications of metabolomics in personalized medicine, increasing R&D funding for pharmaceutical and biotech companies and increasing technological advancements in this market arena.

The market is expected to grow at a compound annual growth rate (CAGR) of 11.9%, reaching around $17.1 billion by 2023.

Major market players include Agilent Technologies Inc., Bio-Rad Laboratories, Bruker Corp., Danaher Corp., Human Metabolome Technologies Inc., LECO Corp., Metabolon Inc., Shimadzu Corp., Thermo Fisher Scientific Inc. and Waters Corp., among others.

Research Highlights

  • By region, North America dominated the market in 2017, accounting for the largest share of the global metabolomics market at 44.9%. This market is projected to reach $7.4 billion by 2023, growing at a CAGR of 11.2%.
  • The Asia-Pacific region is expected to grow at the highest CAGR, 13.4%, due to the growing interest of players, high patient population, improving pharmaceutical and life science infrastructure and increasing healthcare infrastructure in India and China.
  • On the basis of application area, biomarker discovery accounted for the largest share, 30.7%, of the global metabolomics market in 2017. This market is projected to reach $5.5 billion by 2023, growing at a CAGR of 12.9%. However, the toxicology testing application segment is expected to grow at the highest CAGR of 13.2% during the forecast period.

“Metabolomics is a relatively new field compared to genomics and proteomics, which are more mature, but it promises much-needed breakthroughs by virtue of being more descriptive of the actual phenotype or working conditions of the human body,” the report notes. “Genomics describes the body’s code, and proteomics describes the application of that code into the proteins that do the work.”

Editors/reporters requesting analyst interviews should contact Eric Surber at

Metabolomics: Technologies and Global Markets( BIO055C )
Publish Date: Feb 2019    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.